

## **Provisional Draft Agenda**

### **65<sup>th</sup> meeting of the Member State Committee**

**24-27 June 2019**  
ECHA Conference Centre  
Annankatu 18, in Helsinki, Finland

**24 June: starts at 9 am**  
**27 June: ends at 1 pm**

**Item 1 – Welcome and Apologies**

**Item 2 – Adoption of the Agenda**

MSC/A/065/2019  
***For adoption***

**Item 3 – Declaration of specific interests to items on the Agenda**

**Item 4 – Administrative issues**

- Outlook for MSC-66

***For information***

**Item 5 – Minutes of the MSC-64**

- Draft minutes of MSC-64

MSC/M/64/2018  
***For adoption***

**Item 6 – Substance evaluation**

***Closed session for 6.3***

- 1. Written procedure report on seeking agreement on draft decisions on substance evaluation**

***For information***

- 2. Introduction to and preliminary discussion on draft decisions on substance evaluation after MS-CA's/ECHA reactions (*Session 1, open*):**

<b>MSC code</b>	<b>Substance name</b>	<b>EC/List No.</b>
SEV-IT-015/2017 <sup>1</sup>	Quaternary ammonium compounds, tri-C8-10-alkylmethyl, chlorides	264-120-7

SEV-BE-001/2017<sup>1</sup> 2,4-di-tert-butylphenol 202-532-0

SEV-2-SE-032/2013<sup>1</sup> Bis(isopropyl)naphthalene 254-052-6

*For discussion*

**3. Seeking agreement on draft decisions when amendments were proposed by MS-CA's/ECHA (*Session 2, closed*)**

Cases as listed above under 6.2 and any cases stopped in written procedure

*For agreement*

**4. General topics**

Status report on on-going substance evaluation work

*For information*

**Item 7 – Dossier evaluation**

*Closed session for 7.3*

**1. Written procedure report on seeking agreement on draft decisions on dossier evaluation**

*For information*

**2. Introduction to and preliminary discussion on draft decisions on compliance checks and testing proposals when amendments were proposed by MS-CA's (*Session 1, open session*)**

*For discussion followed by agreement seeking under 7.3:*

**Compliance checks**

MSC code	Substance name	EC/List No.
CCH-015/2019	Ethanol, 2,2'-oxybis-, reaction products with ammonia, morpholine derivs. residues	272-712-1
CCH-017/2019 <sup>1</sup>	2-hydroxyethyl acrylate	212-454-9
CCH-020/2019 <sup>1</sup>	Violet sodium polysulfide aluminosilicate with a SOD-type framework structure	701-186-2
CCH-021/2019 <sup>1</sup>	N,N',N'',N'''-tetrakis(4,6-bis(butyl-(N-methyl-2,2,6,6-tetramethylpiperidin-4-yl)-amino)triazin-2-yl)-4,7-diazadecane-1,10-diamine	401-990-0
CCH-022/2019 <sup>1</sup>	N,N',N'',N'''-tetrakis(4,6-bis(butyl-(N-methyl-2,2,6,6-tetramethylpiperidin-4-yl)amino)-triazin-2-yl)-4,7-diazadecane-1,10-diamine	401-990-0
CCH-023/2019 <sup>1</sup>	Cyclohexylidenebis[tert-butyl] peroxide	221-111-2
CCH-033/2019 <sup>1</sup>	Cetrimonium chloride	203-928-6
CCH-037/2019 <sup>1</sup>	Bis(2-(2-butoxyethoxy)ethyl) adipate	205-465-5

**Testing proposal examinations**

MSC code	Substance name	EC/List No.
TPE-049/2019 <sup>1</sup>	Terpineol	701-188-3
TPE-050/2019 <sup>1</sup>	Silver	231-131-3
TPE-053/2019 <sup>1</sup>	Aluminium oxide	215-691-6
TPE-054/2019 <sup>1</sup>	2-(2-thienyl)ethyl toluene-p-sulphonate	254-911-5
TPE-055/2019 <sup>1</sup>	Fatty acids, C16-18 and C18-unsatd., branched and linear, butyl esters	441-620-5

<sup>1</sup> Case to be removed from the agenda if agreed in written procedure in advance of the meeting

*For discussion*

**3. Seeking agreement on draft decisions on compliance checks and testing proposal examinations when amendments were proposed by MS-CA's (Session 2, closed)**

Cases as listed above under 7.2 and any cases stopped in written procedure

*For agreement*

**4. General topics**

- 1) Options for requesting further mutagenicity testing (germ cell or gonadal tissue)  
(Closed session)

*For discussion and agreement*

- 2) Status report on on-going dossier evaluation work

*For information*

**Item 8 – SVHC identification - Seeking agreement on Annex XV proposals for identification of SVHC**

*Timing: Start Day 1 morning*

**1. Written procedure report on seeking agreement on identification of SVHC<sup>2</sup>**

*For information*

**2. Seeking agreement on Annex XV proposals for identification of SVHC<sup>3</sup>**

**Substance**

Tris(4-nonylphenyl, branched and linear) phosphite (TNPP) with  $\geq 0.1\%$  w/w of 4-nonylphenol, branched and linear (4-NP)

2-methoxyethyl acetate (EC No. 203-772-9)

2,3,3,3-tetrafluoro-2-(heptafluoropropoxy)propionic acid, its salts and its acyl halides (covering any of their individual isomers and combinations thereof)

*For discussion and agreement*

**Item 9 – ECHA's recommendations of priority substances to be included in Annex XIV and opinion of MSC**

**1. 9<sup>th</sup> Draft recommendation for inclusion of substances into Annex XIV**

- Update from SECR

*For information and discussion*

- MSC opinion on ECHA's Draft 9<sup>th</sup> recommendation of priority substances to be included in Annex XIV
  - Discussion on the draft MSC opinion
  - Adoption of MSC opinion

*For discussion and adoption*

**2. Draft recommendation to amend entries of DEHP, BBP, DBP, and DIBP in Annex XIV**

- Update from SECR

<sup>2</sup> For any SVHC proposals on which MSC agreement is sought in written procedure.

<sup>3</sup> Cases to be removed from the agenda if the MSC process is not triggered or if agreed in written procedure before the meeting.

***For information and discussion***

- MSC opinion on ECHA's Draft recommendation to amend entries of DEHP, BBP, DBP, and DIBP in Annex XIV
  - Discussion on the draft MSC opinion
  - Adoption of MSC opinion

***For discussion and adoption***

**Item 10 – Opinion of MSC on ECHA's draft update of the Community Rolling Action Plan (CoRAP 2020-2022)**

Invitation for volunteers for the Rapporteurship in drafting the opinion of the MSC on the CoRAP update

- 1) Draft terms of Reference and possible appointment of the Rapporteur and Co-Rapporteur

***For discussion & decision***

**Item 11 – Any other business**

1. Update on appeals and court cases of relevance to MSC

*(Partly closed session)*

***For information***

2. Suggestions from members

***For information***

**Item 12 – Adoption of main conclusions and action points**

- Table with conclusions and action points from MSC-65

***For adoption***